Lice litigation
This article was originally published in The Tan Sheet
Executive Summary
Proposed California class action against lice treatment manufacturers preempted by federal law, San Francisco state court concludes Feb. 20, granting summary judgment for Pfizer/Warner-Lambert and Care Technologies. Plaintiffs filed suit in February 1999, alleging companies failed to warn consumers that lice resistance to pesticides has rendered products such as Rid, Nix and Clear ineffective. Plaintiffs' claims regarding pediculicide product labeling "seek to impose requirements that are 'different from, in addition to, or otherwise not identical' with requirements" of the FD&C Act, Judge David Garcia rules. Plaintiffs' counsel is evaluating whether to appeal. Bayer Consumer Care acquired the Rid line as part of Pfizer's merger with Nix marketer Warner-Lambert in June
You may also be interested in...
OTC Pediculicide Label Statements Not “Voluntary Warranties” – Court
Labeling that uses straightforward language to express information implicit in the applicable OTC monograph does not create a "voluntary warranty," a San Francisco state appeals court recently ruled
OTC Pediculicide Label Statements Not “Voluntary Warranties” – Court
Labeling that uses straightforward language to express information implicit in the applicable OTC monograph does not create a "voluntary warranty," a San Francisco state appeals court recently ruled
Pyrethrum Pediculicide Labeling Revisions Would Provide More Detail – FDA
FDA's proposed amendment of the pediculicide drug products final monograph would appear to bring labeling for such drugs in line with that of OTC lice treatments approved under an NDA